A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Glyburide; Nateglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes diagnosed at least 1 year before inclusion

• Blood glucose criteria must be met

• Microalbuminuria criteria must be met

Exclusion Criteria:

• Pregnant or nursing females or females of childbearing potential not using a medically approved birth control method

• Blood glucose criteria outside the specified range

• Microalbuminuria criteria outside the specified range

• Serious cardiovascular events within the past 6 months

• Other protocol-defined exclusion criteria may apply